Group 1: Company Performance and Goals - The company is confident in achieving its annual target of installing 4,000 units by the end of 2025 [1] - In the first half of 2025, the company plans to install 2,400 units, which is an increase of nearly 5 times compared to the previous year [5] - As of July 10, 2025, the number of shareholders is 20,833 [5] Group 2: Product and Market Insights - FibroScan devices are recognized by multiple authoritative organizations, including WHO and EASL, as a standard for liver disease detection [3] - The global market size for varicose vein ultrasound treatment devices is estimated to be approximately $1.06 billion in 2024 [6] - The company’s device, FibroScan, has a cost of about €10,000 per unit, requiring 250 tests to break even [1] Group 3: Financial and Operational Strategies - The company has conducted special studies to mitigate the impact of currency fluctuations on financial reports [2] - Revenue from the device business, including per-use charges and leasing, amounted to 412 million yuan, accounting for 44.62% of total revenue [7] - The company has transitioned all dollar-denominated funds into euros to minimize exchange rate impacts [6] Group 4: Collaborations and Partnerships - The company collaborates with domestic MASH drug research enterprises for the FibroScan series devices [1] - Echosens, a partner in Europe, operates under a mixed model of direct sales and distribution in certain countries [2] - The company is actively pursuing strategic partnerships to enhance its market presence and product offerings [4]